FDA Finds GLP-1 Drugs Safe, Novartis Deal Nixed

The FDA has not found compelling evidence linking GLP-1 drugs like Wegovy and Ozempic to suicidal thoughts or behaviors, despite concerns raised last year. While the agency is still investigating, it has not seen anything alarming in its review of data from clinical trials and post-market reports. These drugs have been used for decades to manage type 2 diabetes and have more recently been effective in weight loss. Common side effects include gastrointestinal issues, and while rare but serious complications have been reported, the FDA has not confirmed them as established side effects. The FDA recommends that patients not stop taking GLP-1 drugs without consulting their doctor and advises doctors to monitor for any unusual changes in mood or behavior in patients using these medications.